メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
林 宏樹
医学部・腎臓内科学
h-index
617
被引用数
14
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1999
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(86)
類似のプロファイル
(7)
フィンガープリント
Hiroki Hayashiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Acute Kidney Injury
44%
All Cause Mortality
52%
ANCA Associated Vasculitis
18%
Blood Purification
19%
Brain Natriuretic Peptide
14%
Cardiovascular System
42%
Chromosome Protein
14%
Chronic Kidney Disease
54%
Cohort Analysis
74%
Combination Therapy
16%
Creatinine
30%
Cyclophosphamide
16%
Diabetic Nephropathy
24%
Disease
42%
Elderly Patient
16%
End Stage Renal Disease
42%
Fibrosis
17%
Focal Segmental Glomerulosclerosis
19%
Glomerular Filtration Rate
22%
Glucocorticoid
18%
Hazard Ratio
34%
Human Study
16%
Immunoglobulin A Nephropathy
18%
Immunoglobulin G4
44%
Immunosuppressive Treatment
22%
Infection
26%
Interstitial Nephritis
16%
Ischemic Heart Disease
16%
Kidney Function
50%
Lupus Nephritis
59%
Membranous Glomerulonephritis
27%
Minimal Change Disease
50%
Myeloperoxidase
24%
Nephrology
49%
Nephropathy
51%
Nephrosclerosis
14%
Nephrotic Syndrome
70%
Patient with Alzheimer's Disease
14%
Pediatrics
19%
Polycystic Kidney Disease
29%
Proportional Hazards Model
33%
Prospective Cohort Study
66%
Proteinuria
50%
Renal Biopsy
59%
Retrospective Cohort Study
31%
Retrospective Study
14%
Serum Albumin
16%
Short Term Survival
14%
Spinal Cord Tumor
14%
Urinary System
37%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
48%
All Cause Mortality
64%
Alzheimer's Disease
14%
Amyloid
14%
Anemia
14%
Angiotensin
18%
Antianemic Agent
14%
Antihypertensive Agent
14%
Ascites
29%
Bacterial Arthritis
14%
Brain Natriuretic Peptide
14%
Chronic Kidney Failure
57%
Cohort Study
84%
Combination Therapy
18%
Creatinine
26%
Cyclophosphamide
14%
Dapagliflozin
14%
Disease
45%
Disease Course
14%
End Stage Renal Disease
24%
Endocarditis
14%
Ferrous Sulfate
14%
Focal Glomerulosclerosis
19%
Glucocorticoid
14%
Human Study
17%
Hyperuricemia
14%
Hypotension
14%
Immunoglobulin G4
29%
Immunosuppressive Agent
23%
Infection
41%
Inflammation
14%
Ischemic Heart Disease
16%
Kidney Disease
21%
Kidney Polycystic Disease
14%
Membranous Glomerulonephritis
27%
Moraxella
14%
Nephrosclerosis
14%
Nephrotic Syndrome
63%
Nephrotoxicity
14%
Neutrophil Gelatinase Associated Lipocalin
14%
Prospective Cohort Study
100%
Proteinuria
48%
Remission
60%
Renin
18%
Retrospective Study
14%
Short Term Survival
14%
Sodium Glucose Cotransporter 2 Inhibitor
14%
Tolvaptan
14%
Uric Acid
14%
Vitamin D Receptor
14%
Keyphrases
Acute Kidney Injury
29%
Acute Kidney Injury Network Criteria
14%
Adult Patients
17%
All-cause Mortality
22%
Blood Purification
19%
Clinical Practice Guidelines
29%
Confidence Interval
16%
Dialysis Initiation
36%
Early Dialysis
14%
Early Remission
14%
Endocarditis
14%
Ferric Citrate
14%
Ferrous Sulfate
14%
Giant Cell Arteritis
14%
Hazard Ratio
19%
High Mobility Group Box 1 (HMGB1)
14%
Hyperuricemia
14%
IgG4-related Kidney Disease
14%
IgG4-related Tubulointerstitial Nephritis
14%
Immunoglobulin G4-related Kidney Disease
14%
Incident Dialysis Patients
29%
Infection Risk
14%
Infection-related Mortality
19%
Infiltration Rate
14%
Intravenous Cyclophosphamide
14%
Japan
29%
Minimal Change Disease
36%
Moraxella Lacunata
14%
Multicenter Cohort Study
32%
Nephrotic Syndrome
22%
Periaortitis
14%
Pressure-induced
14%
Prospective Cohort Study
18%
Purifier
14%
Racial Heterogeneity
14%
Rare Complication
14%
Regional Variation
14%
Remission of Proteinuria
44%
Renal Hypoperfusion
14%
Septic Arthritis
14%
Serum Uric Acid
14%
Short-acting
14%
Short-term Survival
14%
Skin Ulcer
14%
Sodium Zirconium Cyclosilicate
14%
Spinal Epidural Tumor
14%
Steroid-sensitive
29%
Systematic Lupus Erythematosus
14%
Tertiary Level
14%
Tocilizumab
14%
